⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Global Antiparasitic Drugs (2026-2031) - Rising Prevalence of Parasitic Infections Drives Market Growth
globenewswire.com
JNJ
MRK
NVS
PFE
SNY
TMO
Global Pediatric Drugs (2026-2031) - Rising Prevalence of Childhood Diseases Drives Market Growth
globenewswire.com
PFE
JNJ
GSK
SNY
NVS
PTC
BMRN
JAZZ
GILD
LLY
AMGN
AZN
MRK
ABBV
TAK
Ankylosing Spondylitis Treatment (2026-2031) - Rising Disease Prevalence and Biologic Therapy Adoption Drive Market Growth
globenewswire.com
ABBV
NVS
AMGN
PFE
LLY
JNJ
MRK
GILD
SNY
TAK
Liposome Drug Delivery (2026-2031) - Growing Demand for Targeted Drug Delivery Drives Market Growth
globenewswire.com
GILD
PCAR
JNJ
TEVA
NVS
PFE
MRK
Global Immunomodulators 2026-2031 - Rising Prevalence of Autoimmune Diseases Drives Market Growth
globenewswire.com
BMY
NVS
MRK
AMGN
PFE
LLY
BIIB
AZN
GILD
ABBV
TMO
REGN
IMUX
Pulmonary Edema (2026-2031) - Rising Prevalence of Cardiovascular Diseases Drives Market Growth
globenewswire.com
ABBV
AZN
BSX
BMY
EL
LLY
JNJ
MRK
NVS
PFE
SNY
VTRS
Upper Respiratory Tract Infection Treatment (2026-2031) - Rising Prevalence of Respiratory Infections Drives Market Growth
globenewswire.com
ABT
ABBV
ALC
AZN
BMY
CI
DDS
JNJ
MRK
NVS
PFE
SNY
TEVA
VTRS
AI Disrupts Topical Drug Delivery as Billion-Dollar Partnerships and $3.3 Billion in VC Funding Signal a Structural Shift in Pharmaceutical Formulation
globenewswire.com
LLY
RXRX
NVDA
NVS
SNY
SPRY
Active Pharmaceutical Ingredients (API) Market Report 2026-2036 Just Released — Analyses Synthetic, Biotech, Traditional and Highly Potent APIs
globenewswire.com
MRK
PFE
NVS
Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders
globenewswire.com
NVS